aap

Q2/2015 sales above guidance at EUR 6.5 million; 27% LOQTEQ® growth in H1/2015 - Seite 2

Sales in EUR million H1/2015 H1/2014 Change Trauma 5.6 5.1 11% thereof LOQTEQ® 3.7 2.9 27% Biomaterials 7.6 8.4 -9% Projects 0.2 0.2 10% Other 0.2 0.5 -72% Total sales 13.6 14.2 -4%

 

In the second quarter of 2015, aap Implantate AG increased its LOQTEQ® portfolio sales by 15% compared to the corresponding period in the last year to EUR 2.0 million (Q2/2014: EUR 1.8 million). Sustained by the positive sales development of the LOQTEQ® product family, overall sales in the trauma business were up by 8% year-on-year to EUR 3.2 million (Q2/2014: EUR 2.9 million).

 

In the biomaterials business the company generated sales of EUR 3.2 million (Q2/2014: EUR 4.9 million) in the second quarter of the current financial year. This decline was merely a quarterly fluctuation primarily due to the ordering behaviour of the major customers in the area of bone cement and mixing systems.

 

In the first half of 2015 aap Implantate AG continued the positive sales development of the LOQTEQ® portfolio with an increase of 27% year-on-year to EUR 3.7 million (H1/2014: EUR 2.9 million). In the biomaterials business the company realized sales of EUR 7.6 million (H1/2014: EUR 8.4 million) in the first six months of the current financial year.

 

The preliminary results contained in this press release are based on management's initial analysis of operations for the period ended on 30 June 2015, and are therefore subject to change. aap Implantate AG plans to announce its final results for the second quarter respectively the first half of 2015 on 14 August 2015.

 

About aap Implantate AG